natgillin/translations-raw huggingface dataset:
Novartis Consumer Health SA acting on behalf of all Marketing Authorisation holders (see Annex I) has applied for harmonisation according to Article 30 of 2001/83/EC, as amended, of their products Calcium
Podjetje Novartis Consumer Health SA je v imenu vseh imetnikov dovoljenj za promet (glejte Dodatek
Attn: C. Hatzidakis
Metamorfosis Attikis, Grčija Vročiti: C. Hatzidakis
Calcium-Sandoz® forte 500mg Ca 500mg Effervescent tablets
Calcium-Sandoz® forte 500mg Ca 500mg Šumeče tablete
There is no information of relevance to the safety assessment in addition to what is stated in other parts of the SmPC.
Poleg podatkov, ki so že navedeni v drugih delih povzetka glavnih značilnosti zdravila, ni na voljo drugih pomembnih informacij za oceno varnosti.
Pharmacodynamic properties Pharmacotherapeutic group:
5.1 Farmakodinamične lastnosti Farmakoterapevtske skupina: Minerali
Calcium-Sandoz 500mg Ca2+
500mg Ca2+
An increased fluid intake is recommended for patients prone to formation of calculi in the urinary tract.
Za bolnike, ki so nagnjeni k tvorbi ledvičnih kamnov, je priporočljivo, da pijejo več tekočine.
Pregnancy and lactation
- preprečevanje in zdravljenje pomanjkanja kalcija
Cyprus.
Ciper
Attn: Mr Martin Bischof &
81379 München, Nemčija Vročiti: g. Martin Bischof &
Sandoz 500 mg effervescent tablets (Calcium lactate gluconate + Calcium carbonate 1132 + 875 mg) and Calcium Sandoz 1000 mg effervescent tablets (Calcium lactate gluconate + Calcium carbonate 2263 + 1750 mg).
(kalcijev laktat glukonat + kalcijev karbonat 2263 + 1750 mg).
Metabolism and nutrition disorders:
edem obraza, angionevrotični edem) Presnovne in prehranske motnje:
CALCIUM-SANDOZ Forte
CALCIUMSANDOZ Forte
It is available as capsules (5, 20, 100, 140, 180 and 250 mg).
Na voljo je v obliki kapsul (5 mg, 20 mg, 100 mg, 140 mg, 180 mg in 250 mg).
As a result, the cancer cells cannot divide, slowing down the growth of tumours.
Zaradi tega se rakave celice ne morejo deliti, kar upočasni rast tumorjev.
It is used to treat malignant glioma (brain tumours) in the following groups of patients:
Uporablja se za zdravljenje malignih gliomov (možganskih tumorjev) pri naslednjih skupinah bolnikov:
• adults with newly diagnosed glioblastoma multiforme (an aggressive type of malignant glioma).
• odraslih z na novo diagnosticiranim multiformnim glioblastomom (vrsto zelo agresivnega malignega glioma).
• adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
• odraslih in otrok, starejših od treh let, z malignim gliomom, kakršna sta multiformni glioblastom ali anaplastični astrocitom, če se je tumor po standardnem zdravljenju ponovil ali poslabšal.
The full EPAR for Temozolomide Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Temozolomide Teva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Temozolomide Teva on 28 January 2010.
Evropska komisija je dovoljenje za promet z zdravilom Temozolomide Teva, veljavno po vsej Evropski uniji, izdala 28. januarja 2010.
MTIC binds to the DNA of cells while they are reproducing, which stops cell division.
MTIC se veže na DNK v celicah, medtem ko se te razmnožujejo, kar prepreči njihovo delitev.
Temozolomide Teva should be taken without food.
Zdravilo Temozolomide Teva je treba jemati brez hrane.
This is a summary of the European public assessment report (EPAR) for Temozolomide Teva.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Temozolomide Teva.
This means that Temozolomide Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Temodal.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Temodal.
Temozolomide Teva is used first with radiotherapy and then on its own;
Zdravilo Temozolomide Teva se najprej uporabi skupaj z radioterapijo, nato pa samostojno;
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temozolomide Teva.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
For more information about treatment with Temozolomide Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Temozolomide Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What are the benefits and risks of Temozolomide Teva?
Kakšne so koristi in tveganja, povezani z zdravilom Temozolomide Teva?
Temozolomide Teva should be used with caution in patients with severe liver problems or with kidney problems.
Zdravilo Temozolomide Teva je treba uporabljati previdno pri bolnikih s hudimi težavami z jetri ali ledvicami.
Because Temozolomide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
Ker je zdravilo Temozolomide Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
The CHMP concluded that, in accordance with EU requirements, Temozolomide Teva has been shown to have comparable quality and to be bioequivalent to Temodal.
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Temozolomide Teva primerljivo raven kakovosti kot zdravilo Temodal ter da mu je biološko enakovredno.
Treatment with Temozolomide Teva should be prescribed by a doctor with experience in the treatment of brain tumours.
Zdravljenje z zdravilom Temozolomide Teva lahko predpiše samo zdravnik, ki ima izkušnje z zdravljenjem možganskih tumorjev.
Other information about Temozolomide Teva
Druge informacije o zdravilu Temozolomide Teva
The Committee recommended that Temozolomide Teva be given marketing authorisation.
Priporočil je, da se za zdravilo Temozolomide Teva izda dovoljenje za promet.
Temozolomide Teva is a ‘generic medicine'.
Temozolomide Teva je „generično zdravilo“.
Because Temozolomide Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal.
Ker je zdravilo Temozolomide Teva generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Temodal.
The active substance in Temozolomide Teva, temozolomide, belongs to a group of cancer medicines called alkylating agents.
Zdravilna učinkovina zdravila Temozolomide Teva, temozolomid, spada v skupino zdravil proti raku, imenovanih alkilirajoči citostatiki.
In the body, temozolomide is converted to another compound called MTIC.
Temozolomid se v telesu pretvori v drugo spojino, imenovano monometil triazenoimidazol karboksamid (MTIC).
Temozolomide Teva is a cancer medicine.
Temozolomide Teva je zdravilo proti raku.
Temozolomide Teva is a medicine that contains the active substance temozolomide.
Temozolomide Teva je zdravilo, ki vsebuje zdravilno učinkovino temozolomid.
The dose of Temozolomide Teva depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day.
Odmerek zdravila Temozolomide Teva je odvisen od telesne površine (izračunane glede na telesno višino in maso bolnika) in sega od 75 do 200 mg na kvadratni meter, enkrat na dan. Odmerek in število odmerkov sta odvisna od vrste zdravljenega tumorja ter od tega, ali je bil bolnik že zdravljen, ali se zdravilo Temozolomide Teva uporablja samostojno oziroma skupaj z drugimi zdravljenji in kako se bolnik odziva na zdravljenje.
Therefore, the CHMP's view was that, as for Temodal, the benefit outweighs the identified risk.
Zato je menil, da tako kot pri zdravilu Temodal koristi odtehtajo znana tveganja.
Why has Temozolomide Teva been approved?
Zakaj je bilo zdravilo Temozolomide Teva odobreno?
Patients may also need to take medicines to prevent vomiting before taking Temozolomide Teva.
Preden bo bolnik vzel zdravilo Temozolomide Teva, bo morda potreboval tudi zdravilo za preprečevanje bruhanja.
How has Temozolomide Teva been studied?
Kako je bilo zdravilo Temozolomide Teva raziskano?
What is Temozolomide Teva?
Kaj je zdravilo Temozolomide Teva?
Temozolomide Teva is used on its own in these patients.
Pri teh bolnikih se zdravilo Temozolomide Teva uporablja kot samostojno zdravilo.
How is Temozolomide Teva used?
Kako se zdravilo Temozolomide Teva uporablja?
What is Temozolomide Teva used for?
Za kaj se zdravilo Temozolomide Teva uporablja?
How does Temozolomide Teva work?
Kako zdravilo Temozolomide Teva deluje?
Date of first authorisation: 30 July 2007 Date of latest renewal: 30 July 2012
Datum prve odobritve: 30. julij 2007 Datum zadnjega podaljšanja: 30. julij 2012
Stimulants (analeptics) must not be used.
Stimulantov (analeptikov) ne smete uporabljati.
The following combinations are not recommended:
Naslednje kombinacije niso priporočljive:
The tablet may be taken with or without food.
Tableto se lahko vzame s hrano ali brez.
Patients should be carefully monitored.
Bolnike je treba skrbno spremljati.
Risks of abuse
Tveganje za zlorabe
The recommended dosage and the duration of treatment should not be exceeded.
Priporočenega odmerka in dolžine zdravljenja se ne sme prekoračiti.
Do not take this medicine for more than 10 days continuously unless your doctor tells you to do so.
Tega zdravila ne smete neprekinjeno jemati dlje kot 10 dni, razen če vam je to predpisal vaš zdravnik.
After emergency treatment, medical monitoring of the patient should be continued.
Po urgentnem zdravljenju je treba nadaljevati z medicinskim spremljanjem bolnika.
If you suddenly stop treatment, depression may occur.
Če nenadoma prenehate z zdravljenjem, se lahko pojavi depresija.
• painful or difficult urination
• boleče ali oteženo uriniranje
Not known: frequency cannot be estimated from the available data • abnormal behaviour
Neznana pogostnost: pogostnosti iz razpoložljivih podatkov ni mogoče oceniti • nenormalno vedenje
The following side effects have been seen in studies:
Naslednje neželene učinke so opazili v študijah:
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Pogostnost je definirana kot: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Caution should be exercised in the following patient groups:
Previdnost je potrebna pri naslednjih skupinah bolnikov:
• trouble sleeping
• težave s spanjem
The duration of treatment should be kept as short as possible and should not be continued after the symptoms have disappeared.
Zdravljenje naj bo čim krajše in z njim ne smete nadaljevati po izginotju simptomov.
Distribution Desloratadine is moderately bound (83 % - 87 %) to plasma proteins.
Porazdelitev Desloratadin se zmerno veže (83-87 %) na plazemske beljakovine.
If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule.
Če ste pozabili pravočasno vzeti odmerek zdravila, ga vzemite čimprej, potem pa nadaljujte s svojim običajnim režimom odmerjanja zdravila.
• increased sugar in blood
• povečana koncentracija sladkorja v krvi
Adults and adolescents 12 years of age and over The recommended dose is one tablet twice daily with a glass of water, with or without food.
Odrasli in mladostniki, stari 12 let ali več Priporočeni odmerek je ena tableta dvakrat na dan s kozarcem vode, s hrano ali brez.
Patients should be informed that most people do not experience drowsiness.
Bolnike je treba obvestiti, da se zaspanost pri večini ljudi ne pojavi.
• sugar in urine
• sladkor v urinu
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
Študije na živalih ne kažejo neposrednih ali posrednih škodljivih učinkov na sposobnost razmnoževanja (glejte poglave 5.3).
Swallow the tablet whole with water.
Tablete pogoltnite cele z vodo.
Do not take tablets more often than recommended.
Tablet ne jemljite pogosteje, kot je priporočeno.
The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded.
Encima, ki je odgovoren za presnovo desloratadina, še niso ugotovili, zato nekaterih interakcij z drugimi zdravili ni mogoče popolnoma izključiti.
The tablet may be taken with a full glass of water but must be swallowed entirely (without crushing, breaking or chewing it).
Tableto se lahko vzame s polnim kozarcem vode, vendar jo je treba pogoltniti celo (brez drobljenja, lomljenja ali žvečenja).
The prevalence of this poor metabolizer phenotype was greater among Black adults than Caucasian adults (18 % vs. 2 %) however the safety profile of these subjects was not different from that of the general population.
Prevalenca tega fenotipa slabih metabolizatorjev med odraslimi črnci je bila sicer večja kot med odraslimi belci (18 % v primerjavi z 2 %), vendar se profil varnosti pri njih ni razlikoval od profila varnosti zdravila pri splošni populaciji.
• tricyclic antidepressants and other antihistamines.
• tricikličnimi antidepresivi in drugimi antihistaminiki.
What Aerinaze is and what it is used for
Kaj je zdravilo Aerinaze in za kaj ga uporabljamo
What you need to know before you take Aerinaze
Kaj morate vedeti, preden boste vzeli zdravilo Aerinaze
In the event of overdose, symptomatic and supportive treatment immediately should be started and maintained it for as long as necessary.
V primeru prevelikega odmerjanja je treba nemudoma uvesti simptomatično in podporno zdravljenje, ki naj traja tako dolgo, kot je potrebno.
In clinical trials involving 414 adults the most frequent of adverse reactions reported were insomnia (8.9 %), dry mouth (7.2 %) and headache (3.1 %).
V kliničnih preskušanjih, v katerih je sodelovalo 414 odraslih oseb, so najpogosteje poročali o naslednjih neželenih učinkih: nespečnost (8,9 %), suha usta (7,2 %) in glavobol (3,1 %).
These effects may be more likely to occur in adolescents from 12 years old, elderly patients, or in cases of overdose (see section 4.9).
Bolj verjetno je, da se ti učinki pojavijo pri mladostnikih, starejših od 12 let, starostnikih ter v primeru prevelikega odmerjanja (glejte poglavje 4.9).
Taking Aerinaze is not recommended if you are pregnant.
Jemanje zdravila Aerinaze ni priporočljivo, če ste noseči.
• changes in frequency of urination
• sprememba pogostnosti uriniranja
This medicine is for oral use.
To zdravilo je za peroralno uporabo.
Keep the blisters in the outer carton in order to protect from light.
Pretisne omote shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Continuous use may lead to taking more Aerinaze than the recommended dose to get the desired effect, resulting in an increased risk of overdosing.
Neprekinjena uporaba lahko vodi do potrebe po večjem odmerku zdravila Aerinaze od priporočenega, da bi dosegli želeni učinek, kar pomeni povečano tveganje za preveliko odmerjanje.
• digitalis (see section 4.4)
• z digitalisom (glejte poglavje 4.4),
Desloratadine does not readily penetrate the central nervous system.
Desloratadin ne prehaja zlahka v osrednje živčevje.
Other medicines and Aerinaze
Druga zdravila in zdravilo Aerinaze
It is advisable to limit treatment to about 10 days, as during chronic administration the activity of pseudoephedrine sulphate may diminish.
Priporočljivo je, da dolžino zdravljenja omejite na približno 10 dni, saj lahko pri kronični uporabi aktivnost psevdoefedrinijevega sulfata postopoma upada.
Do not use this medicine after the expiry date which is stated on the outer carton and blister after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP.
The active substance and its metabolite are excreted in urine; 55-75 % of the administered dose is excreted unchanged.
Učinkovina in njen presnovek se izločata z urinom, pri čemer se od 55 do 75 % danega odmerka izloči v nespremenjeni obliki.
Therefore, if surgery is scheduled, it is preferable to discontinue treatment 24 hours before anaesthesia.
Če je predviden kirurški poseg, je torej najbolje prenehati zdravljenje 24 ur pred anestezijo.
Posology The recommended dose of Aerinaze is one tablet twice a day.
Odmerjanje Priporočeni odmerek zdravila Aerinaze je ena tableta dvakrat na dan.
In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine.
V vrsti farmakokinetičnih in kliničnih preskušanj je bila pri 6 % preiskovancev dosežena večja koncentracija desloratadina.
Some patients may present a toxic psychosis with delusions and hallucinations.
Nekateri bolniki imajo lahko celo toksično psihozo z blodnjami in halucinacijami.
If you forget to take Aerinaze
Če ste pozabili vzeti zdravilo Aerinaze
The combination was not more toxic than their individual components, and observed effects were generally related to the pseudoephedrine sulphate component.
Ta kombinacija tudi ni bila bolj toksična od njenih ločenih sestavin, ugotovljeni učinki pa so bili na splošno vezani na psevdoefedrinijev sulfat.
Do not crush, break or chew.
Ne smete jih zdrobiti, zlomiti ali žvečiti.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
V vsaki kategoriji pogostnosti so neželeni učinki razporejeni po padajoči resnosti.
Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1receptor antagonist activity.
Desloratadin je nesedativen dolgotrajno delujoč antagonist histamina s selektivnim delovanjem na periferne receptorje H1.
At the recommended dose, this medicine is not expected to affect your ability to drive or use machines.
Pri uporabi priporočenih odmerkov tega zdravila ni pričakovati, da bi le-to vplivalo na vašo sposobnost za vožnjo in upravljanje strojev.
Athletes taking Aerinaze may have positive doping-tests.
Športniki, ki jemljejo zdravilo Aerinaze, bodo lahko imeli pozitiven izvid doping testa.
• hyperthyroidism,
• hipertiroidizmom,
The clinical efficacy and safety of Aerinaze tablets was evaluated in two, 2-week multicentre, randomized parallel group clinical trials involving 1,248 patients 12 to 78 years of age with seasonal allergic rhinitis, 414 of whom received Aerinaze tablets.
Klinično učinkovitost in varnost zdravila Aerinaze tablete so ovrednotili v dveh 2-tedenskih multicentričnih randomiziranih kliničnih preskušanjih vzporednih skupin pri skupaj 1248 bolnikih s sezonskim alergijskim rinitisom, starih od 12 do 78 let, od katerih je 414 jemalo zdravilo Aerinaze tablete.
Pharmacodynamic effects The pharmacodynamic effects of Aerinaze tablets are directly related to that of its components.
Farmakodinamični učinki zdravila Aerinaze tablete so neposredno povezani s farmakodinamiko njegovih sestavin.
If you are scheduled to have surgery, your doctor may advise you to stop taking Aerinaze 24 hours beforehand.
Če ste naročeni na kirurški poseg, vam bo vaš zdravnik morda svetoval, da 24 ur pred posegom prenehate z jemanjem zdravila Aerinaze.
No pre-clinical studies have been performed with Aerinaze.
Predkliničnih študij zdravila Aerinaze niso izvedli.
If signs and symptoms such as pyrexia, erythema or many small pustules are observed, administration of Aerinaze should be discontinued and appropriate measures taken if needed.
Če se pojavijo znaki in simptomi, kot so pireksija, eritem ali večje število majhnih pustul, je treba prekiniti zdravljenje z zdravilom Aerinaze in, če je potrebno, uvesti ustrezne ukrepe.
Desloratadine is not removed by haemodialysis and it is not known if it is eliminated by peritoneal dialysis.
Desloratadin se ne odstranjuje s hemodializo in tudi ni znano, ali ga je iz telesa mogoče odstraniti s peritonealno dializo.
Use in children and adolescents Do not give this medicine to children less than 12 years of age.
Uporaba pri otrocih in mladostnikih Tega zdravila ne dajajte otrokom, mlajšim od 12 let.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden vzamete to zdravilo.
In case of alkalinisation of the urine, a partial resorption takes place.
V primeru alkalizacije urina lahko pride do delne resorpcije učinkovine.
The safety and efficacy of Aerinaze in children below the age of 12 years have not been established.
Varnost in učinkovitost zdravila Aerinaze pri otrocih, mlajših od 12 let, nista bili dokazani.
Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicinal product.
Čeprav večina ljudi ne postane zaspanih, je priporočljivo, da ne opravljate dejavnosti, ki zahtevajo zbranost, na primer vožnje avtomobila ali upravljanje strojev, dokler ne ugotovite vašega odziva na zdravilo.
Aerinaze with alcohol
Zdravilo Aerinaze skupaj z alkoholom
Caution should be exercised in patients suffering from migraine who are currently being treated with ergot alkaloid vasoconstrictors (see section 4.5).
Previdnost je potrebna pri bolnikih, ki imajo migrene in se trenutno zdravijo z vazokonstriktorji iz skupine ergot alkaloidov (glejte poglavje 4.5).
EU/1/07/399/001 2 modified-release tablets EU/1/07/399/002 4 modified-release tablets EU/1/07/399/003 7 modified-release tablets EU/1/07/399/004 10 modified-release tablets EU/1/07/399/005 14 modified-release tablets EU/1/07/399/006 20 modified-release tablets
EU/1/07/399/001 2 tableti s podaljšanim sproščanjem EU/1/07/399/002 4 tablete s podaljšanim sproščanjem EU/1/07/399/003 7 tablet s podaljšanim sproščanjem EU/1/07/399/004 10 tablet s podaljšanim sproščanjem EU/1/07/399/005 14 tablet s podaljšanim sproščanjem EU/1/07/399/006 20 tablet s podaljšanim sproščanjem
Do not take more tablets than recommended on the label.
Ne jemljite več tablet, kot je priporočeno.
The administration of Aerinaze should be discontinued at least 48 hours before skin tests since antihistamines maybe prevent or reduce otherwise positive reaction to dermal reactivity index.
Bolnik mora prenehati z jemanjem zdravila Aerinaze najmanj 48 ur pred kožnimi testi, ker lahko antihistaminiki preprečijo ali zmanjšajo sicer pozitivno reakcijo in zmanjšajo indeks kožnega odziva.
Desloratadine does not inhibit CYP3A4 in vivo, and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.
Desloratadin ne zavira CYP3A4 in vivo, študije in vitro pa so pokazale, da zdravilo ne zavira CYP2D6 in da ni ne substrat ne zaviralec P-glikoproteina.
Speak with your doctor, pharmacist or nurse regarding whether you can drink alcohol while taking Aerinaze.
Pogovorite se s svojim zdravnikom, s farmacevtom ali z medicinsko sestro, če lahko pijete alkohol, medtem ko jemljete zdravilo Aerinaze.
Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.
Zdravstveni delavci lahko razmislijo o ukinitvi desloratadina pri bolnikih, ki med zdravljenjem doživijo epileptični napad.
• Patients receiving digitalis (see section 4.5)
• pri bolnikih, ki prejemajo digitalis (glejte poglavje 4.5).